Companies › Shenzhen Ausa Pharmed
2 active drug programs in 8 registered trials: 6 Phase 4, 1 Phase 3, 1 Phase 2; Cardiovascular, Neurology; next expected readout Jun 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 5-methyltetrahydrofolate (5-MTHF) Active form of folate; methyl donor for homocysteine remethylation | – | Phase 4 | Hypertension | Jun 2029 |
| Amlodipine Voltage-gated L-type calcium channel blocker | Ion channels | Phase 4 | Hypertension; Atrial Fibrillation; Diabetes Mellitus, Type 2; Stroke … | Jun 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06424834 | Amlodipine | Phase 2 | Angina Pectoris | Cardiovascular | Dec 2026 |
| NCT04111419 | Amlodipine | Phase 4 | Atrial Fibrillation | Cardiovascular | Dec 2026 |
| NCT04111419 | Amlodipine | Phase 4 | Atrial Fibrillation | Cardiovascular | Dec 2026 |
| NCT03264352 | Amlodipine | Phase 4 | Diabetes Mellitus, Type 2 | Cardiovascular | Sep 2028 |
| NCT04974151 | Amlodipine | Phase 4 | Hypertension | Cardiovascular | Jun 2029 |
| NCT04974151 | 5-methyltetrahydrofolate (5-MTHF) | Phase 4 | Hypertension | Cardiovascular | Jun 2029 |
| NCT05155137 | Amlodipine | Phase 3 | Stroke | Neurology | Dec 2029 |
| NCT04974138 | Amlodipine | Phase 4 | Hypertension | Cardiovascular | Jun 2030 |
Grace Therapeutics SPH Qingdao Growful Pharmacetical MedTrace Pharma CeleCor Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.